The Risk of Psychiatric Disorders in Finasteride Users With Benign Prostatic Hyperplasia and Androgenetic Alopecia: A Population-Based Case-Control Study
November 2024
in “
Australasian Journal of Dermatology
”
New to Finasteride? There is a guide in the encyclopedia. Read the guide → 
Studysummary This article critiques a study on finasteride use among individuals with benign prostatic hyperplasia and androgenetic alopecia, highlighting the flawed methodology and potential confounding effects of hair loss on mental health, which confuses interpretation of psychiatric risk.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The document critiques a study on the risk of psychiatric disorders in finasteride users with benign prostatic hyperplasia (BPH) and androgenetic alopecia (AGA), highlighting methodological issues. It argues that the study is mislabelled as a case-control study when it is actually a retrospective cohort study, leading to potential confusion and misinterpretation of results. The study's control group, which lacks AGA, introduces confounding factors, making it difficult to attribute mental health outcomes solely to finasteride use. The critique emphasizes the importance of accurately reporting study methodologies to ensure reliable conclusions and facilitate future research.
